Q1 2023 Earnings Call Transcript April 15, 2025 Spruce Biosciences, Inc. misses on earnings expectations. Reported EPS is $-0.57 EPS, expectations were $-0.21. Operator: Welcome to the Spruce ...

TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. In March 2024, in a Type C meeting ... 2025. 42.2 million shares ...

Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB ... like growth factor 2 via an amino acid ...